The feasibility of ureteral tissue engineering using autologous veins: an orthotopic animal model with long term results

Journal of Negative Results in Biomedicine

Georg Bartsch³  Richard E Hautmann¹  Axel Haferkamp³  Jens Mani³  Kilian M Gust³  Björn G Volkmer²  Robert de Petriconi¹  Oliver Engel⁴ 

[1] Department of Urology, University Medical Center Ulm, Prittwitzstr. 43, 89075 Ulm, Germany;Department of Urology, Kassel, Germany;Department of Urology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60486 Frankfurt, Germany;Department of Urology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany

关键词: Vein;    Urothelial cells;    Ureter;    Tissue engineering;    Reconstruction;   

Others  :  1133139
DOI  :  10.1186/1477-5751-13-17

 received in 2014-05-23, accepted in 2014-10-23,  发布年份 2014

【 摘 要 】

Background

In an earlier study we demonstrated the feasibility to create tissue engineered venous scaffolds in vitro and in vivo. In this study we investigated the use of tissue engineered constructs for ureteral replacement in a long term orthotopic minipig model. In many different projects well functional ureretal tissue was established using tissue engineering in animals with short-time follow up (12 weeks). Therefore urothelial cells were harvested from the bladder, cultured, expanded in vitro, labelled with fluorescence and seeded onto the autologous veins, which were harvested from animals during a second surgery. Three days after cell seeding the right ureter was replaced with the cell-seeded matrices in six animals, while further 6 animals received an unseeded vein for ureteral replacement. The animals were sacrificed 12, 24, and 48 weeks after implantation. Gross examination, intravenous pyelogram (IVP), H&E staining, Trichrome Masson’s Staining, and immunohistochemistry with pancytokeratin AE1/AE3, smooth muscle alpha actin, and von Willebrand factor were performed in retrieved specimens.

Results

The IVP and gross examination demonstrated that no animals with tissue engineered ureters and all animals of the control group presented with hydronephrosis after 12 weeks. In the 24-week group, one tissue engineered and one unseeded vein revealed hydronephrosis. After 48 weeks all tissue engineered animals and none of the control group showed hydronephrosis on the treated side. Histochemistry and immunohistochemistry revealed a multilayer of urothelial cells attached to the seeded venous grafts.

Conclusions

Venous grafts may be a potential source for ureteral reconstruction. The results of so far published ureteral tissue engineering projects reveal data up to 12 weeks after implantation. Even if the animal numbers of this study are small, there is an increasing rate of hydronephrosis revealing failure of ureteral tissue engineering with autologous matrices in time points longer than 3 months after implantation. Further investigations have to prove adequate clinical outcome and appropriate functional long-term results.

【 授权许可】

   
2014 Engel et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

【 参考文献 】

• [1]Png JC, Chapple CR: Principles of ureteric reconstruction. Curr Opin Urol 2000, 10(3):207-212.
• [2]Brito-Juarez M, Volkmer BG, Gschwend JE, Hautmann RE, Bartsch GC Jr: Tissue engineered venous matrices for potential applications in the urogenital tract. Tissue Eng 2007, 13(10):2475-2482.
• [3]Tachibana M, Nagamatsu GR, Addonizio JC: Ureteral replacement using collagen sponge tube grafts. J Urol 1985, 133(5):866-869.
• [4]Duchene DA, Jacomides L, Ogan K, Lindberg G, Johnson BD, Pearle MS, Cadeddu JA: Ureteral replacement using small-intestinal submucosa and a collagen inhibitor in a porcine model. J Endourol 2004, 18(5):507-511.
• [5]Liatsikos EN, Dinlenc CZ, Kapoor R, Bernardo NO, Pikhasov D, Anderson AE, Smith AD: Ureteral reconstruction: small intestine submucosa for the management of strictures and defects of the upper third of the ureter. J Urol 2001, 165(5):1719-1723.
• [6]Osman Y, Shokeir A, Gabr M, El-Tabey N, Mohsen T, El-Baz M: Canine ureteral replacement with long acellular matrix tube: is it clinically applicable? J Urol 2004, 172(3):1151-1154.
• [7]Dahms SE, Piechota HJ, Nunes L, Dahiya R, Lue TF, Tanagho EA: Free ureteral replacement in rats: regeneration of ureteral wall components in the acellular matrix graft. Urology 1997, 50(5):818-825.
• [8]Koziak A, Kania P, Marcheluk A, Dmowski T, Szczesniewski R, Dorobek A: Reconstructive surgery of the extensive ureter strictures using human dura mater allografts. Ann Transplant 2004, 9(4):12-16.
• [9]Royce PL, Zimmern PE, de Kernion JB: Patch grafting the renal pelvis and ureteropelvic junction. A comparative study in pigs using lyophilized dura mater and free peritoneum. Urol Res 1988, 16(1):37-41.
• [10]Varady S, Friedman E, Yap WT, Lage A, Richie JP: Ureteral replacement with a new synthetic material: Gore-Tex. J Urol 1982, 128(1):171-175.
• [11]Baltaci S, Ozer G, Ozer E, Soygur T, Besalti O, Anafarta K: Failure of ureteral replacement with Gore-Tex tube grafts. Urology 1998, 51(3):400-403.
• [12]Sabanegh ES Jr, Downey JR, Sago AL: Long-segment ureteral replacement with expanded polytetrafluoroethylene grafts. Urology 1996, 48(2):312-316.
• [13]De Filippo RE, Yoo JJ, Atala A: Urethral replacement using cell seeded tubularized collagen matrices. J Urol 2002, 168(4 Pt 2):1789-1792. discussion 1792–1783
• [14]Matsunuma H, Kagami H, Narita Y, Hata K, Ono Y, Ohshima S, Ueda M: Constructing a tissue-engineered ureter using a decellularized matrix with cultured uroepithelial cells and bone marrow-derived mononuclear cells. Tissue Eng 2006, 12(3):509-518.
• [15]Nomi M, Atala A, Coppi PD, Soker S: Principals of neovascularization for tissue engineering. Mol Aspects Med 2002, 23(6):463-483.
• [16]De Coppi P, Delo D, Farrugia L, Udompanyanan K, Yoo JJ, Nomi M, Atala A, Soker S: Angiogenic gene-modified muscle cells for enhancement of tissue formation. Tissue Eng 2005, 11(7–8):1034-1044.
• [17]Soker S, Machado M, Atala A: Systems for therapeutic angiogenesis in tissue engineering. World J Urol 2000, 18(1):10-18.
• [18]Dorin RP, Pohl HG, De Filippo RE, Yoo JJ, Atala A: Tubularized urethral replacement with unseeded matrices: what is the maximum distance for normal tissue regeneration? World J Urol 2008, 26(4):323-326.
• [19]Klippel KF, Hohenfellner R: Umbilical vein as ureteral replacement. Invest Urol 1979, 16(6):447-450.
• [20]Kjaer TB, Nilsson T, Madsen PO: Total replacement of part of the canine urethra with lyophilized vein homografts. Invest Urol 1976, 14(2):159-161.
• [21]Hubner W, Rurka I, Porpaczy P, Miko I: Autologous everted vein graft for repairing long-section urethral defects. Urol Res 1991, 19(2):131-134.
• [22]Pompeius R, Ekroth R: Vein patch grafting for repair of short ureteric strictures. Scand J Urol Nephrol 1977, 11(3):245-247.
• [23]Oberpenning F, Meng J, Yoo JJ, Atala A: De novo reconstitution of a functional mammalian urinary bladder by tissue engineering. Nat Biotechnol 1999, 17(2):149-155.